“Investigators used the 12-week trial to test XP23829 against a placebo on the commonly used Psoriasis Area and Severity Index (PASI) score, scoring reductions for a once-daily 800-mg pill that almost doubled a placebo response and did significantly better at 400 mg (-38% on PASI compared to a PASI reduction of -25% for the placebo). The twice-daily 400-mg dose also edged the single, daily 800-mg pill.”
“Detailing the side effects of this drug, though, investigators noted 22% to 40% of the patients in the drug arms suffered from diarrhea. "There were two treatment emergent serious adverse events assessed as possibly related to treatment with XP23829: acute cholecystitis and enterocolitis. Both subjects recovered." There were also significantly higher rates of abdominal pain and vomiting in the 800-mg arm. And one in 20 patients had grade 2 lymphopenia--low levels of protective lymphocytes in the blood--with 15% in the grade 1 category.”
That’s the results from a drug that generated this.
“Under the deal, XenoPort will receive a $47.5 million up-front payment and an additional $2.5 million for transfer of certain clinical trial materials to Dr. Reddy's Laboratories.”
News 
Market Data 
Discover 
AI
